Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              MC2 Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora® Cream for Plaque Psoriasis

              Contact the Supplier

              Lead Product(s): Calcipotriol,Betamethasone Dipropionate

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Almirall

              Deal Size: Undisclosed Upfront Cash: $18.0 million

              Deal Type: Collaboration February 17, 2021

              Details:

              In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

              MC2 Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              MC2 Therapeutics Announces FDA Approval of Wynzora® Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis

              Contact the Supplier

              Lead Product(s): Calcipotriol,Betamethasone

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 22, 2020

              Details:

              The FDA approval is based on the results of the US Phase 3 clinical trial1 against active comparator Taclonex® Topical Suspension (calcipotriene and betamethasone dipropionate.

              PharmaCompass__DigitalAd